DDX3X and neoplasm: Moreover, recent findings revealed that DDX3 inhibition activates a tumor-intrinsic type I interferon response via cytosolic dsRNA sensing and reduces surface PD-L1 levels, which may enhance antitumor immunity and improve the efficacy of immune checkpoint blockade [60,79].